Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 89.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health (ELAN) delivered earnings and revenue surprises of 25% and 3.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -40% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Green Thumb Industries Inc. (GTBIF) Q4 Earnings Lag Estimates
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -28.57% and 1.78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks.com featured highlights Chimerix, Vista Oil & Gas and Arcus Biosciences
by Zacks Equity Research
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.
Buy 3 of the Best Stocks by Using Net Income Ratio
by Tirthankar Chakraborty
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
Chimerix (CMRX) Beats Q3 Earnings Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are anticipated to have enhanced consumer engagement across all CVS Health businesses in Q3.
What's in the Cards for Illumina (ILMN) in Q3 Earnings?
by Zacks Equity Research
The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q4 Earnings
by Zacks Equity Research
Hologic's (HOLX) Molecular Diagnostics sales are likely to have been affected by the significant drop in demand for COVID-19 testing.
Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.
Factors Setting the Tone for HCA Healthcare (HCA) Q3 Earnings
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are expected to reflect better emergency room visits and outpatient surgeries, partly offset by the continued incidence of labor costs.
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
by Zacks Equity Research
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Implied Volatility Surging for Chimerix (CMRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chimerix (CMRX) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights Emergent BioSolutions, Chimerix and SIGA Technologies
by Zacks Equity Research
Emergent BioSolutions, Chimerix and SIGA Technologies have been included in this Analyst Blog.